Long-term Safety in Epstein-Barr Virus-Seropositive Kidney-only Transplant Recipients Treated With Belatacept in Clinical Practice: Final Study Results From the ENLiST Registry.
Christian P LarsenFlavio VincentiTzuyung D KouCraig A ShadurBarbara BresnahanStanley C JordanE Steve WoodleNelson GoesJohn VellaDavid WojciechowskiMartin S PolinskyAndres Gomez-CamineroPublished in: Transplantation direct (2024)
Our results from the ENLiST registry, a large, prospective real-world study, showed that the incidence rates of PTLD and CNS PTLD in belatacept-treated EBV-seropositive transplant recipients were consistent with findings from previous phase 3 trials.